You are here

Article Text

Article menu
Download PDFPDF
Review
Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs
  1. J Martel-Pelletier,
  2. D Lajeunesse,
  3. P Reboul,
  4. J-P Pelletier
  1. Osteoarthritis Research Unit, Centre hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, Québec H2L 4M1 Canada
  1. Correspondence to:
    Professor J Martel-Pelletier, Osteoarthritis Research Unit, CHUM, Hôpital Notre-Dame, 1560 rue Sherbrooke Est, Pavillon deSève, Montréal (Québec) H2L 4M1, Canada;
    jm{at}martelpelletier.ca

Abstract

Dual 5-LOX/COX inhibitors are potential new drugs to treat inflammation. They act by blocking the formation of both prostaglandins and leucotrienes but do not affect lipoxin formation. Such combined inhibition avoids some of the disadvantages of selective COX-2 inhibitors and spares the gatrointestinal mucosa.

  • cyclo-oxygenase
  • leucotrienes
  • 5-lipoxygenase
  • lipoxin
  • AUC, area under the curve
  • COX, cyclo-oxygenase
  • FLAP, 5-lipoxygenase activating-protein
  • GI, gastrointestinal
  • IL, interleukin
  • 5-LOX, 5-lipoxygenase
  • LT, leucotriene
  • LX, lipoxin
  • NO, nitric oxide
  • NSAIDs, non-steroidal anti-inflammatory drugs
  • PG, prostaglandin
  • PMN, polymorphonuclear cells
  • TXA2
  • thromboxane A2

https://doi.org/10.1136/ard.62.6.501

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes